Form 4: Gilead Sciences Director, Jeffrey Bluestone, Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Director Jeffrey Bluestone reports acquisition of stock options and restricted stock units in Gilead Sciences, Inc.
Summary
- On May 7, 2025, Jeffrey Bluestone, a director of Gilead Sciences, Inc., reported the acquisition of 6,809 non-qualified stock options and 1,516 restricted stock units (RSUs).
- The stock options have an exercise price of $98.9 and expire on May 7, 2035.
- The RSUs represent the contingent right to receive one share of Gilead Sciences, Inc.'s common stock each.
- Both the stock options and RSUs vested immediately upon the grant date.
- Following the reported transactions, Bluestone beneficially owns 6,809 derivative securities and 5,713 shares of common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices. The immediate vesting could be seen as a positive signal of confidence.
Positives
- The immediate vesting of both the stock options and RSUs suggests confidence in the director's continued contribution to the company's success.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It reflects standard practices for incentivizing and retaining key personnel.
Comparison to Industry Standards
- Stock option grants and RSU awards are common compensation tools used by companies like Gilead Sciences to align the interests of directors and shareholders.
- Companies such as Amgen, Johnson & Johnson, and Pfizer also utilize similar equity-based compensation plans for their executives and directors.
- The vesting schedules and terms of these grants are generally in line with industry standards, although immediate vesting is less common than graded vesting over several years.
Stakeholder Impact
- The grant of stock options and RSUs aligns the director's interests with those of shareholders, incentivizing them to work towards increasing the company's value.
Key Dates
| Date | Description |
|---|---|
| 05/07/2025 | Date of earliest transaction, grant date of stock options and restricted stock units, and vesting date. |
| 05/08/2025 | Date of signature on the Form 4 filing. |
| 05/07/2035 | Expiration date of the non-qualified stock options. |
Keywords
Gilead Sciences, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, GILD
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.